Core Viewpoint - Ascencio has received a transparency declaration indicating that Carl, Eric, and John Mestdagh, along with their controlled companies, now hold a total of 787,418 voting rights, representing an 11.94% shareholding in the company [1]. Group 1 - The Mestdagh family has crossed the 5% threshold in their shareholding, with Carl Mestdagh and CMHC SRL being the key individuals involved in this increase [1].

Core Viewpoint - Sagimet Biosciences Inc. is advancing the development of denifanstat (ASC40), a fatty acid synthase (FASN) inhibitor, which has shown positive results in clinical trials for treating moderate to severe acne, indicating its potential as a novel therapeutic option in this area [1][2][3]. Clinical Results - The Phase 3 open-label trial (ASC40-304) enrolled 240 subjects who received denifanstat 50 mg once daily for up to 40 weeks, following a previous 12-week double-blind trial [4]. - Denifanstat demonstrated improvements in all efficacy endpoints beyond the 12-week results, including significant reductions in skin lesion counts and improvements in Investigator's Global Assessment (IGA) scores [5][6]. Safety Profile - Denifanstat was generally well tolerated, with only mild to moderate treatment-emergent adverse events (TEAEs) reported, including dry eye syndrome (5.5%) and dry skin (5.2%) [7]. - No serious adverse events (SAEs) related to denifanstat were reported, and all adverse events were manageable, with no permanent discontinuations due to treatment [7]. Market Context - Acne affects over 50 million people in the U.S., with a significant number requiring chronic management, highlighting the need for effective treatment options [9]. - The inhibition of FASN is considered a promising approach due to its role in sebum production and inflammatory pathways associated with acne [9].

Group 1 - The Ordinary General Meeting of Shareholders of Ascencio SA on 30 January 2026 approved all proposed resolutions, primarily concerning the financial statements for the year ended 30 September 2025 [1] - A total of 1,779,647 shares, representing 27% of the total shares, were represented at the meeting [1] Group 2 - The Meeting approved a gross dividend distribution of EUR 4.45 per share [2] - The Meeting granted discharge to the sole statutory director and the Statutory Auditor for their performance [2] - The compensation report and provisions related to change of control were also approved by separate vote [2]

Core Insights - Ardmore Shipping Corporation will host its 2026 Investor Day on February 12, 2026, at 12:00 P.M. Eastern Time in New York City, where it will present its strategy and capital allocation framework along with the 4Q 2025 financial results [2][3] Group 1: Company Overview - Ardmore operates a fleet of MR product and chemical tankers ranging from 25,000 to 50,000 deadweight tonnes, providing seaborne transportation of petroleum products and chemicals globally [5] - The company's core strategy focuses on developing a modern, high-quality fleet, building long-term commercial relationships, and maintaining cost advantages while creating synergies and economies of scale [6] Group 2: Market Update - At the Investor Day, Ardmore's senior management will provide an update on product and chemical tanker markets, covering supply and demand fundamentals, evolving trade patterns, and the impact of geopolitical volatility on trade routes and vessel demand [3]

Core Viewpoint - Ascletis Pharma Inc. announced positive topline results from a Phase III open-label study of denifanstat (ASC40), a first-in-class oral fatty acid synthase (FASN) inhibitor for treating moderate-to-severe acne vulgaris, indicating a potential breakthrough in acne treatment [1] Group 1: Study Results - Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile in a Phase III open-label study involving 240 patients, with most treatment-emergent adverse events (TEAEs) being mild (grade 1) or moderate (grade 2) [1] - No grade 3 or 4 adverse events or serious adverse events (SAEs) related to denifanstat (ASC40) were reported, and no deaths occurred during the study [1] Group 2: Mechanism of Action - The mechanism of action for denifanstat (ASC40) includes direct inhibition of sebum production by inhibiting de novo lipogenesis (DNL) in human sebocytes and reducing inflammation by decreasing cytokine secretion and Th17 differentiation [1] - This unique mechanism sets denifanstat (ASC40) apart from most other acne treatments, which do not address the underlying cause of acne [1] Group 3: Regulatory Progress - The New Drug Application for denifanstat (ASC40) for acne has been accepted by the China National Medical Products Administration, indicating progress towards commercialization [1] Group 4: Company Overview - Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing and commercializing potential best-in-class and first-in-class therapeutics for metabolic diseases [1] - The company utilizes proprietary technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) to develop multiple drug candidates, including small molecules and peptides [1]

Core Insights - Ascletis Pharma Inc. is advancing its investigational drug ASC30, a GLP-1 receptor agonist, into a Phase II study for type 2 diabetes, with topline data expected in Q3 2026 [2][5] Group 1: ASC30 Development - ASC30 has shown a placebo-adjusted weight loss of up to 7.7% in a completed 13-week Phase II study for obesity, demonstrating better gastrointestinal tolerability compared to other treatments [1][3] - The Phase II study for diabetes will evaluate ASC30's efficacy, safety, and tolerability, focusing on changes in HbA1c and body weight among approximately 100 participants [5][6] - ASC30 is designed for once-daily oral administration and has been developed in-house by Ascletis as a first and only investigational small molecule GLP-1R fully biased agonist [4][6] Group 2: Clinical Study Details - The obesity Phase II study involved 125 participants and reported a treatment discontinuation rate due to adverse events of 4.8% [3] - The study for diabetes is randomized, double-blind, and placebo-controlled, with participants assigned to different dosages of ASC30 [5] - The primary endpoint of the diabetes study is the mean change in HbA1c from baseline, with secondary endpoints including fasting blood glucose and body weight changes [5]

Core Viewpoint - Ardmore Shipping Corporation (ASC) is given a buy rating due to a strong outlook for the product tanker market and favorable trading conditions for the company [1]. Group 1: Company Analysis - The company is currently trading at attractive levels, which enhances its investment appeal [1]. - The product tanker market is expected to perform well, contributing positively to ASC's financial prospects [1]. Group 2: Market Outlook - The overall outlook for the product tanker market is strong, indicating potential growth and profitability for companies operating in this sector [1].

Core Viewpoint - Ardmore Shipping Corporation (ASC) is given a buy rating due to a strong outlook for the product tanker market and favorable trading conditions for the company [1]. Group 1: Company Analysis - The company is positioned well in the product tanker market, which is expected to perform strongly [1]. - Ardmore Shipping Corporation is currently trading at attractive levels, enhancing its investment appeal [1]. Group 2: Market Outlook - The product tanker market is anticipated to experience growth, contributing positively to the company's performance [1].

Core Viewpoint - Ascencio has announced the acquisition of the Horizon Provence retail park in Monteux, France, for €22.8 million excluding VAT, aligning with its strategic focus on retail assets in attractive locations [1][6]. Group 1: Acquisition Details - The retail park covers an area of over 12,000 m² and consists of around twenty retail units, primarily featuring food retailers, which aligns with Ascencio's strategy [2][6]. - The acquisition is financed entirely through borrowings using available secured credit lines, and it is in line with the market value determined by an independent valuer [5]. Group 2: Location and Accessibility - The retail park is situated in a rapidly growing residential and tourist area in the Provence-Alpes-Côte d'Azur region, benefiting from high visibility and accessibility along the main road connecting Avignon to Carpentras [3]. - Its proximity to leisure parks and hotel complexes enhances its attractiveness as a retail complex [3]. Group 3: Sustainability Features - The asset is located near soft mobility hubs and has received BREEAM certification, indicating its sustainability credentials [4]. - It is equipped with 8 charging stations, nearly 1,500 m of photovoltaic panels, and around 1,000 m of shading systems [4]. Group 4: Financial Impact - The acquisition is expected to have an immediate positive annual impact of €0.07 on Ascencio's EPRA Earnings per share and will result in an increase of approximately 1.7% in its EPRA LTV ratio [5]. Group 5: Strategic Alignment - The transaction aligns with Ascencio's strategy of focusing on retail assets in suburban areas with a strong commercial mix centered around food retailers [6]. - The integration of Horizon Provence exemplifies Ascencio's selective and disciplined growth strategy aimed at creating long-term value [6].

Core Insights - Ascletis Pharma Inc. announced positive topline results from a Phase I clinical trial for ASC50, an oral small molecule inhibitor targeting IL-17, indicating favorable safety, tolerability, and pharmacokinetics [3][5][7] Group 1: Clinical Trial Results - The Phase I clinical trial was randomized, double-blind, and placebo-controlled, involving 46 healthy participants who received varying doses of ASC50 [3] - ASC50 demonstrated a dose-proportional pharmacokinetic profile from 10 mg to 600 mg, with an elimination half-life ranging from 43 to 104 hours depending on the dose [1][2][8] - All adverse events reported were mild and transient, with no serious adverse events or discontinuations noted during the study [8] Group 2: Target Engagement and Efficacy - Strong target engagement was observed with elevated plasma IL-17A levels persisting until day 7 for higher doses of ASC50 [1][8] - The drug showed higher absolute oral bioavailability and longer half-life compared to another IL-17 inhibitor currently in clinical development [8] Group 3: Future Development - Based on the positive results, ASC50 is advancing to the next phase of clinical development, focusing on multiple ascending doses in participants with mild to moderate plaque psoriasis [5] - ASC50 is positioned as a potential best-in-class oral small molecule IL-17 inhibitor, developed using Artificial Intelligence-assisted Structure-Based Drug Discovery technology [6][7]